Successful first year of the Digital In Vivo Alliance
As we near the end of 2023, we want to celebrate a successful first year for the Digital In Vivo Alliance, recognizing the dedication, passion, and leadership of our members. Let’s reflect on some key achievements that have shaped our path in 2023:
FOSTERING A DIGITAL IN VIVO COMMUNITY
• Hosted our first in person meeting in Farmington, Connecticut, laying the groundwork for digital biomarker development prioritization.
• Proudly hosted our inaugural networking reception and convened for a second in person meeting in Salt Lake City, Utah, serving as valuable platforms to engage with peers, share progress, and strengthen collaboration.
• Expanded our network and exchanged insights with organizations with similar interests including the The 3Rs Collaborative (3RsC), Digital Medicine Society (DiMe), and the FDA.
• Launched https://DIVA.bio, providing a centralized platform for communicating with our growing community.
STRATEGIC PILLARS
Established our mission, vision, and goals and formulated strategic pillars that serve as a framework for our collective efforts.
V3 FRAMEWORK ADOPTION
Embracing the need for scientific rigor, adopted and adapted the V3 Framework (https://lnkd.in/gmQnAVwD) to serve as the foundation for digital biomarker validation.
EMPOWERING IMPACT
• Focus groups, comprised of scientists, veterinarians, and data scientists played a pivotal role in establishing a portfolio of digital measures and designing and executing in vivo rodent studies in neuro-epilepsy, neuromotor disease, respiratory disease, dermatitis, safety/toxicology assessment, and animal health, husbandry, and welfare, fueling biomarker development.
• Preparations for the next phase of studies in 2024, including a cross-site reproducibility study, underscores our dedication to reliability and validity.
DIGITAL IN VIVO DATA ENVIRONMENT
Launched a collaborative platform for DIVA members to develop and share data and algorithms.
MACHINE LEARNING HACKATHONS
Demonstrated commitment to collaborative digital biomarker development through two impactful ML hackathons.
KNOWLEDGE SHARING TRIUMPHS
• Presented at conferences including, Safety Pharmacology Society, AALAS, American Epilepsy Society, and The Jackson Laboratory Short Course on the Application of Machine Learning for Automated Quantification of Behavior (https://lnkd.in/gHKHJHhn).
• Contributions to manuscripts for a Frontiers in Toxicology Research Topic on AI-based digital caging technology in toxicology and safety pharmacology testing demonstrate a commitment to sharing valuable scientific insights.
These milestones are a testament to what we can achieve when we work together. Each of our members has played a crucial role in our shared success. Here’s to a thriving future together and for the Digital In Vivo Alliance!
